Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Ling

Showing results (121-130 of 164) with videos related to

Pageof 17
Sort By:
The American Journal of Drug and Alcohol Abuse|August 23, 2011
Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trialSudie E Back, Rebecca L Payne, Amy Herrin Wahlquist, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 23, 2014
Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice"George Woody, Douglas Bruce, P Todd Korthuis, et al.
Synapse (New York, N.Y.)|May 21, 2005
Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusersBradley Voytek, Steven M Berman, B Daniel Hassid, et al.
Contemporary Clinical Trials|February 2, 2010
A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodologyRoger D Weiss, Jennifer Sharpe Potter, Scott E Provost, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|May 25, 2006
Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attritionSandy Venneman, Andrew Leuchter, George Bartzokis, et al.
Substance Abuse|November 2, 2010
United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resource Centres: TreatnetJuana Tomás-Rosselló, Richard A Rawson, Maria J Zarza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 23, 2014
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trialGeorge E Woody, Douglas Bruce, P Todd Korthuis, et al.
The American Journal of Drug and Alcohol Abuse|September 30, 2008
Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysisElmer Yu, Karen Miotto, Evaristo Akerele, et al.
Addiction (Abingdon, England)|August 8, 2013
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxoneRichard N Rosenthal, Walter Ling, Paul Casadonte, et al.
Addiction (Abingdon, England)|January 20, 2009
Buprenorphine tapering schedule and illicit opioid useWalter Ling, Maureen Hillhouse, Catherine Domier, et al.
Pageof 17

Showing results (121-130 of 164) with videos related to

Sort By:
Pageof 17
The American Journal of Drug and Alcohol Abuse|August 23, 2011
Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trialSudie E Back, Rebecca L Payne, Amy Herrin Wahlquist, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 23, 2014
Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice"George Woody, Douglas Bruce, P Todd Korthuis, et al.
Synapse (New York, N.Y.)|May 21, 2005
Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusersBradley Voytek, Steven M Berman, B Daniel Hassid, et al.
Contemporary Clinical Trials|February 2, 2010
A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodologyRoger D Weiss, Jennifer Sharpe Potter, Scott E Provost, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|May 25, 2006
Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attritionSandy Venneman, Andrew Leuchter, George Bartzokis, et al.
Substance Abuse|November 2, 2010
United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resource Centres: TreatnetJuana Tomás-Rosselló, Richard A Rawson, Maria J Zarza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 23, 2014
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trialGeorge E Woody, Douglas Bruce, P Todd Korthuis, et al.
The American Journal of Drug and Alcohol Abuse|September 30, 2008
Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysisElmer Yu, Karen Miotto, Evaristo Akerele, et al.
Addiction (Abingdon, England)|August 8, 2013
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxoneRichard N Rosenthal, Walter Ling, Paul Casadonte, et al.
Addiction (Abingdon, England)|January 20, 2009
Buprenorphine tapering schedule and illicit opioid useWalter Ling, Maureen Hillhouse, Catherine Domier, et al.
Pageof 17